-
Nepal floods leave trail of destruction, aid challenge
-
Kinshasa urban train back on track after years to beat gridlock
-
Experts outline sustainable ways to declutter Australian homes
-
Merino crossbreeding plan tests Himachal Pradesh wool ambitions
-
Bulk book purchases feed AI training through destructive scanning
-
Pringles launches thicker Dippers range for US snack market
-
George and Amal Clooney attend Lake Como event after France evacuation
-
US and Venezuela announce 65-billion-barrel oil development agreement
-
Michelle Obama describes relief and adjustment after daughters leave home
-
Assistance-dog dispute puts Great Bernera community groups under financial strain
-
Very strong El Niño forecast to peak during southern African summer
-
Sello Hatang remembers actor Sol Rachilo through a personal archive
-
SAFA opens tender for dressing rooms, ablutions and grandstands
-
UN committee calls on South Africa to dismantle racist vigilante groups
-
TEEKS brings Māori-rooted soul and a new view of masculinity to South Africa
-
South African creators seek stronger businesses beyond brand partnerships
-
Saudi customs seize 1.95 million amphetamine pills in lentil shipment
-
Syria warns Israeli actions could push region toward wider war
-
Trump says Russia will not attack NATO as CIA chief visits Moscow
-
East Midlands Railway warns of bank holiday disruption at St Pancras
-
British Museum schedules new Bayeux Tapestry ticket release
-
Six treated after sign falls at Big Church Festival in West Sussex
-
From forced labour to living heritage: Sao Tome's colonial plantations
-
Norway, in mourning, enters a new era under Haakon VIII
-
Motorola September 2026 Deals: Up to $700 Off Razr Ultra and Moto G
-
Number of missing in Nepal, China floods soars to nearly 3,000
-
In war-split Myanmar 'spirit consorts' commune across divide
-
Number of missing in Nepal, China floods soars past 2,400
-
Leaders of Russia, China, Iran to attend summit in Kyrgyzstan
-
Trump announces deal for huge US stake in Venezuelan oil reserves
-
Hovland and Gerard share lead at Tour Championship
-
Kane confirms talks on Bayern extension
-
Maresca salutes 'unbelievable' Cherki after Man City star sinks Palace
-
Trump govt. mulls deal to give away part of Yosemite park
-
Marquinhos rescues last-gasp draw for PSG at Lille in Ligue 1
-
Indian release of Sonia Gandhi memoir uncertain after publisher clarification
-
ICE detains British far-right activist Milo Yiannopoulos in Louisiana
-
Cities show cleaner transport policies can reduce severe air pollution
-
Milo Yiannopoulos held by ICE after missing immigration hearing
-
Four patients harmed in Nashville hospital medication mix-up
-
Six Flags closes X2 rollercoaster after reports of severe brain injuries
-
Essex council hires private guards as Wethersfield asylum centre expands
-
Jury ends second day without verdict in Lindsay Clancy murder trial
-
Haakon VIII becomes Norway's king after Harald V dies at 89
-
Artist says criticised Ronnie O'Sullivan mural is unfinished
-
Six injured after sign falls at Christian festival in West Sussex
-
UAE grants Starlink 10-year satellite broadband licence
-
Dubai airport expands scanners that keep laptops and liquids in bags
-
US says Hormuz mines cleared as diplomacy and military deployments continue
-
Kuwait and Pakistan sign military cooperation agreement
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
L.AbuAli--SF-PST